Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open, multicentre phase I clinical study to assess the tolerability of fulvestrant 500 mg in postmenopausal women with hormone receptor positive advanced or recurrent breast cancer.

Next Previous
Search
Trial Profile

An open, multicentre phase I clinical study to assess the tolerability of fulvestrant 500 mg in postmenopausal women with hormone receptor positive advanced or recurrent breast cancer.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors AstraZeneca

    • Most Recent Events

    • 16 Nov 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 16 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Planned end date changed from 1 Mar 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top